Pasi A. Jänne

发表

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

Geoffrey R. Oxnard, C. Paweletz, P. Jänne, 2015, Clinical Cancer Research.

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer

A. Redig, P. Jänne, M. Capelletti, 2015, Clinical Cancer Research.

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

John R. Engen, Kwok-Kin Wong, Liang Chen, 2009, Nature.

The quest to overcome resistance to EGFR-targeted therapies in cancer

P. Jänne, C. Chong, Pasi A. Jänne, 2013, Nature Medicine.

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Karen Cichowski, A. Letai, R. Berkowitz, 2015, Cell.

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2010, Molecular Cancer Therapeutics.

LKB1 modulates lung cancer differentiation and metastasis

D. Neil Hayes, David C. Christiani, Kwok-Kin Wong, 2007, Nature.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Haiyun Wang, John C. Hunter, Shuai Li, 2018, Cell.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Andrew L. Kung, Matthew D. Wilkerson, Michael D. Cameron, 2012, Nature.

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Nathanael Gray, P. Jänne, N. Gray, 2009, Nature Reviews Drug Discovery.

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

Donna Neuberg, Benjamin L. Ebert, Scott A. Armstrong, 2019, Science.

Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

Matthew Meyerson, M. Meyerson, P. Jänne, 2004, Cancer Research.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2011 .

Erratum: Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine (American Journal of Human Genetics (2016) 98(6) (1067–1076) (S0002929716301069) (10.1016/j.ajhg.2016.04.011))

Sara Chandros Hull, Robert C. Green, Sean D. Mooney, 2016 .

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

Haikuo Zhang, Gerald Lelais, Kwok-Kin Wong, 2016 .

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer

Taebo Sim, Takayuki Kosaka, Nathanael S. Gray, 2016, Clinical Cancer Research.

Drug discovery: Inhibitors that activate

Karen Cichowski, P. Jänne, K. Cichowski, 2010, Nature.